Co-X Portfolio Company Xalud Therapeutics Secures $30M to Advance Novel Gene Therapy

Written By Mark Adkison

We are thrilled to announce that our portfolio company, Xalud Therapeutics, has successfully closed an oversubscribed $30 million Series C financing.

This significant investment will fuel the expansion of Xalud's clinical programs for its proprietary, non-viral gene therapy platform. Their lead candidate, XT-150, is being developed to treat multiple chronic inflammatory diseases, including osteoarthritis and peripheral neuropathic pain, by targeting a master regulator of the immune system.

Congratulations to the entire Xalud team on this incredible milestone! We are proud to be part of their journey to transform patient care for chronic inflammation.

Read the full article —-> HERE

LinkedIn article ——> HERE

Mark Adkison
Previous

Co-X Partner Vantaca Reaches Unicorn Status with $300M+ Growth Investment
Next

Beyond the Bottom Line: Why We Invest in Workplace Wellness